Cloudnine draws four global PE suitors after earlier failed IPO attempt

Roughly four years back, Cloudnine Group of Hospitals tried and failed to build enough investor confidence to list publicly, with that attempt pegging the maternity and paediatric hospital operator’s worth at around ₹4,000 crore. The company now finds itself in a very different position: buyout funds TPG Capital, Advent International, CVC Capital Partners and Permira have reportedly been shortlisted to begin due diligence on a stake purchase that would value the business at close to ₹11,000 crore, according to multiple media reports. Some earlier reports had suggested a wider pool of interested funds, including Warburg Pincus, KKR and Kedaara Capital, before the field narrowed to the present four contenders.

Deal structure
The transaction under discussion is expected to centre on a complete exit by existing investor True North, which first backed Cloudnine in 2015 and holds roughly a quarter of the company. Depending on how the final valuation shakes out and how much capital the business needs, Cloudnine may also issue an additional 5 to 10 per cent of fresh shares to whichever fund wins the process. Two other existing backers, Temasek, which came in during 2024, and TPG NewQuest, a separate entity from bidder TPG Capital that has held a stake since 2021, together control about 52 per cent of the company and are expected to stay on as shareholders regardless of the outcome. Investment bank Allegro Capital is said to be running the sale process, with binding offers expected by early August.

What changed since the shelved listing
Several developments appear to explain why Cloudnine now commands nearly triple its earlier valuation. The company has pulled in new institutional funding, paid down close to ₹75 crore of debt, and expanded its network to more than 40 centres from roughly half that number previously. It has also struck acquisitions to broaden its footprint, most notably a deal reported in May 2026 to take over the maternity, childcare and fertility operations of Apollo Health and Lifestyle, a transaction that valued those businesses at about ₹1,550 crore. As part of that arrangement, Apollo Health and Lifestyle is set to hold on to a 9.9 per cent stake in the combined entity, making it the largest non-financial investor, with the merged group expected to run more than 55 centres once the integration is complete.

One person tracking the private equity sector, speaking to an industry publication, suggested that the underlying strategy has been to build scale and revenue first, with a public listing to follow once the company is a larger and more established target for public market investors.

Margins tell a different story
Despite the jump in valuation, geographic reach and revenue, Cloudnine’s operating margins are understood to have stayed roughly flat through this period of expansion, a detail that sits somewhat at odds with the scale of investor interest the company is now attracting.

A conservative take on the numbers
The roughly threefold rise in Cloudnine’s implied valuation, from about ₹4,000 crore to about ₹11,000 crore, has coincided with real, verifiable changes: new capital raised, debt reduced by about ₹75 crore, the centre count roughly doubled, and a sizeable bolt-on acquisition of Apollo’s maternity and fertility business layered on top. These are the kind of changes that plausibly justify a higher valuation. What is harder to reconcile is those same reports indicating operating margins have not moved much even as revenue and footprint expanded, which suggests that much of the valuation increase is being priced on future scale and eventual profitability rather than on demonstrated improvement in unit economics today. Because the current stake sale is still at the due-diligence stage, with binding bids not expected until early August, the ₹11,000-crore figure should be read as an indicative, not final, valuation, and the eventual price could move in either direction once the shortlisted funds complete their review of the business.
MB Bureau